1. OP0229 Effect of baseline serum crp levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies. (15th June 2017) Authors: Westhovens, R; Kavanaugh, A; Jamoul, C; Tasset, C; Harrison, P; Aa, A Van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks. (15th June 2017) Authors: Alten, R; Westhovens, R; Kavanaugh, A; Genovese, M; Winthrop, K; Greenwald, M; Ponce, L; Enriquez, F; Stanislavchuk, M; Mazur, M; Spindler, A; Cseuz, R; Nikulenkova, N; Glowacka-Kulesz, M; Szombati, I; Dudek, A; Meuleners, L; Tasset, C; Harrison, P; Aa, A Van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0182 Monotherapy with the jak1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients. (15th June 2017) Authors: Kavanaugh, A; Aa, A Van der; Jamoul, C; Li, W; Goyal, L; Pan, Y; Harrison, P; Tasset, C; Tarrant, J; Galien, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 270 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0205 Effects of the jak1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate. (15th June 2017) Authors: Genovese, MC; Li, W; Goyal, L; Pan, Y; Aa, A Van der; Jamoul, C; Harrison, P; Tasset, C; Galien, R; Tarrant, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients. (15th June 2017) Authors: Taylor, P; Westhovens, R; Aa, A Van der; Jamoul, C; Li, W; Goyal, L; Pan, Y; Harrison, P; Tasset, C; Tarrant, J; Galien, R Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗